Top news from MedWatch this week
Monday
GN Hearing’s Veterans Affairs market share drops to eight-year low – failed launch to blame
FDA awards priority review to Genmab and Abbvie’s cancer candidate
Teva CEO steps down, replacement found
Analyst: Multibillion-dollar obesity market estimate could boost Novo trading
Tuesday
Novo Nordisk invests over USD 740m in Danish facility
Novo’s Danish facility expansion will free up production capacity
Lundbeck counts on employee growth despite economic turmoil
New GN product will win Veterans Affairs market shares, bank assesses
Wednesday
Teva denies outgoing CEO board role
Strained Danish job market poses challenge for Novo’s newest expansion
Scandinavian life science cluster praises ”significant” Novo decision to invest in Denmark
Thursday
Ambu retires main argument for single-use endoscopes
Denmark recommends Lundbeck migraine treatment
WSA and Philips raise prices after discount ends at Costco
Analysts agree: Kåre Schultz was the right man for Teva – for a time
Friday
Denmark rejects Gilead and Eisai cancer drugs
Danish reimbursement committee submits diabetes reassessment proposal for feedback
